Navigation Links
New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation
Date:11/14/2011

in in patients with sHF at baseline (PRADAXA 150mg: 3.10%; warfarin: 3.90%) and those without sHF (PRADAXA 150mg: 3.39%; warfarin: 3.45%).(1) There was no significant interaction for major bleeding events between the two subgroups of patients (HR = 0.79 for patients with sHF; 0.99 for patients without sHF; p-value for interaction = 0.74).(1) Additionally, annual rates of intracranial bleeding were lower with PRADAXA 150mg twice daily than warfarin in patients with sHF at baseline (PRADAXA 150mg: 0.26%; warfarin: 0.65%) and those without sHF (PRADAXA 150mg: 0.34%; warfarin: 0.80%).(1) There was no significant interaction for intracranial bleeding events between the two subgroups of patients (HR = 0.39 for patients with sHF; 0.42 for patients without sHF; p-value for interaction = 0.72).(1)

"It is important that we continue to analyze the data from RE-LY to better understand the use of PRADAXA in different types of non-valvular atrial fibrillation patients," said John Smith, MD, PhD, senior vice president for clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "Boehringer Ingelheim is committed to informing physicians about the clinical implications for patients taking PRADAXA through data analyses such as these."

PRADAXA was approved by the U.S. Food and Drug Administration in October 2010 to reduce the risk of stroke and systemic embolism in patients with NVAF.(6) PRADAXA has been shown to reduce both ischemic and hemorrhagic stroke compared to warfarin in patients with NVAF.(6)  In the first eleven months after approval, more than 420,000 patients in the U.S. were prescribed PRADAXA.(7) Dabigatran is recommended in a 2011 update to atrial fibrillation treatment guidelines.

Additional RE-LY Subanalysis Presented at AHA

A second subanalysis assessed the risk of peri-operative bleeding with PRADAXA 150mg twice daily compared to warfarin in patients undergoing surgery (n = 4,615).(8) 
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Clinilabs will Conduct Phase 1 Trial Using QTinno®
3. Bright Light into the Ear Canal Treats Seasonal Depression Effectively in Two Clinical Trials Presented by Valkee and University of Oulu
4. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
5. Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer
6. NeuroCog Trials Appoints Industry Executive Michael Hufford, Ph.D. to Chief Operating Officer
7. Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer
8. Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting
9. Data From REMEDEE Trial Featuring OrbusNeichs Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011
10. Conatus Pharmaceuticals Terminates Phase 2 Clinical Trial of CTS-1027
11. CTRI Confirms Leading Indian CRO Supports Majority of Hemophilia Trials in India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
(Date:12/22/2014)... 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, announced ... University of Calgary in conjunction with co-authors from Kyoto ... validates the company,s ongoing clinical research using dermal sheath ... baldness. The paper entitled " Hair Follicle ...
(Date:12/22/2014)... ITRA Global, one of the largest organizations ... estate, has further expanded its global reach with the ... Western Australia, reports Mylinda Vick, CCIM, Chairman of the ... / ACORPP (Australian Corporate Property and Projects) , is ... services to a wide range of clients in the ...
(Date:12/19/2014)... , Dec. 19, 2014 Naurex Inc., ... novel drugs for diseases of the central nervous system, ... and chief executive officer, will present at the 33 ... presentation will take place at 3:00 p.m. PST on ... in San Francisco, Calif. ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... The bread and butter of Wisconsins economic growth will ... capital to transfer our best technology to the marketplace, ... and ensuring theres a 21st century infrastructure in place ... side to the equation, too, that may prove as ...
... a provider of supply chain execution (SCE) ... supplier compliance and inbound productivity by providing ASN ... Link and CatalystConnect SL are part of ... OAG (Open Application Group) XML interface standards. The ...
... WI Governor Jim Doyle today announced his "Grow ... of the recommendations is to increase broadband and ... , ,Mike Tye, AT&T regional vice present of ... encouraged by the "Grow Wisconsin" initiative unveiled today ...
Cached Biology Technology:Athletics, pop culture and the arts 2Athletics, pop culture and the arts 3Software Enables Suppler Customer Data Integration 2
(Date:12/22/2014)... 2014 Research and Markets ... of the "The Global Watermarking and ... http://photos.prnewswire.com/prnh/20130307/600769 ... of the global digital media watermarking and ... monitor piracy by securely and invisibly embedding ...
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today ... differences in genetic ancestry of individuals from across ... immigrants first arrived more than four hundred years ago, ... as a meeting place for peoples from different continents. ... mixing of peoples with African, European, and American origins ...
(Date:12/17/2014)...  HITLAB SM announced today its completion ... confirm its adherence to current U.S. Food and ... to conduct regulated smart device and smart phone ... safety and research quality. "HITLAB is ... delivery with innovative technology," said Laura Pugliese ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... Scientific progress in Huntington,s disease (HD) relies upon the ... the disease,s genetics and/or pathophysiology. Large animal models, such ... rodent models, including a larger brain that is amenable ... more human-like neuro-architecture. Three articles in the latest issue ...
... to osteoporosis are a major cause of disability or premature ... who have already suffered one fragility fracture; they are at ... others who have not fractured. Nevertheless health care ... these patients, leaving them exposed to debilitating and life-threatening secondary ...
... and wild plants has concluded they are under threat ... decline or loss could have profound environmental, human health ... services to about 75% of crop species and enable ... Pollination services provided by insects each year worldwide are ...
Cached Biology News:Large animal models of Huntington's disease offer new and promising research options 2Large animal models of Huntington's disease offer new and promising research options 3Large animal models of Huntington's disease offer new and promising research options 4New review sets international standards for best practice in fracture liaison services 2Cocktail of multiple pressures combine to threaten the world's pollinating insects 2
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
TRIAL SIZE Anti-Kaede [2F4] Monoclonal Research Focus: tag Storage: -20C Shipping Temperature: 4C...
AANAT [Arylalkylamine N-acetyltransferase; EC 2.3.1.87]...
TUP1 Market Segment: Molecular Biology...
Biology Products: